CN109847039A - A kind of Chinese medicine composition and application thereof for treating breast cancer - Google Patents
A kind of Chinese medicine composition and application thereof for treating breast cancer Download PDFInfo
- Publication number
- CN109847039A CN109847039A CN201910232807.0A CN201910232807A CN109847039A CN 109847039 A CN109847039 A CN 109847039A CN 201910232807 A CN201910232807 A CN 201910232807A CN 109847039 A CN109847039 A CN 109847039A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- breast cancer
- medicine composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a kind of Chinese medicine compositions for treating breast cancer, are made of the Chinese medicine material of following parts by weight: 15-25 parts of Radix Astragali, 15-25 parts of Tupistra, 15-25 parts of oldenlandia diffusa, 10-20 parts of Poria cocos, 15-20 parts of trigone, 15-20 parts of luffa, 15-20 parts of fritillaria thunbergii, 15-20 parts of leech, 10-20 parts of Radix Curcumae, 15-20 parts of Prunella vulgaris, 15-20 parts of curcuma zedoary, 15-20 parts of Sargent gloryvine, 10-20 parts of thallus laminariae, 15-20 parts of lycopodium calvatum, 10-20 parts of dandelion, 10-25 parts of spina gleditsiae, 3-6 parts of radix bupleuri.Chinese medicine composition of the invention can promote breast cancer mouse apoptosis of tumor cells, inhibited to breast cancer；The Chinese medicine composition can inhibit tumor proliferation by the expression of up-regulation caspase-3.
Description
Technical field
The present invention relates to Traditional Chinese medicine compound composition technical fields, and in particular to a kind of Chinese medicine composition for treating breast cancer and
Its purposes.
Background technique
Breast cancer is the malignant tumour occurred in mammary gland galandular epithelium tissue.99% occurs in women in breast cancer, and male is only
Account for 1%.Breast cancer is to threaten one of most common malignant disease of women's health, " China in 2017 of National Cancer Center publication
Tumour registration annual report " display, breast cancer occupies female malignant incidence first place, annual new cases about 27.9 ten thousand, and with every
The speed increase in year 2% or so, Annual average mortality rate is more than 70,000.The treatment method of breast cancer specifically includes that operation, radiotherapy, change
Treatment, endocrine therapy and targeted therapy etc., although radiation and chemotherapy method can effectively kill cancer cell, side effect is non-
Chang great.
Another important method of the traditional Chinese medicine as oncotherapy, also plays certain curative effect in the treatment of breast cancer.
There is the natural Chinese medicinal herb that can much enhance immunity of organism, and without any side effects in Chinese medicine.Chinese medicine can make up operation and control
It treats, radiotherapy, the deficiency of chemotherapy.
Chinese medicinal granule is the mode of traditional Chinese medicine decoction decocting to be copied, by the prepared slices of Chinese crude drugs using modern science and technology
Through the refined single medicinal material product of the techniques such as extraction, concentration, drying.Product maintains the nature and flavor and effect of the prepared slices of Chinese crude drugs,
Quality is reliable and stable, examines the allotment of prescription applied to Chinese medicine, adapt to it is dialectical treat, the needs of prescription variation, and be not required to decoct
It boils, is convenient to take, absorbing the advantages that quick, dosage is accurate, safely cleaning, carrying convenience.Chinese medicinal granule is for Chinese medicine
Bed formula uses, and can flexibly be added and subtracted according to tcm prescription.
Summary of the invention
The purpose of the present invention is a kind of Chinese medicine composition for treating breast cancer, what this Chinese medicine composition had breast cancer
Inhibiting effect.
In order to achieve the above object, a kind of Chinese medicine composition for treating breast cancer provided by the invention, by following parts by weight
Chinese medicine material be made: 15-25 parts of Radix Astragali, 15-25 parts of Tupistra, 15-25 parts of oldenlandia diffusa, 10-20 parts of Poria cocos, trigone
15-20 parts, 15-20 parts of luffa, 15-20 parts of fritillaria thunbergii, 15-20 parts of leech, 10-20 parts of Radix Curcumae, 15-20 parts of Prunella vulgaris, cowherb
15-20 parts of art, 15-20 parts of Sargent gloryvine, 10-20 parts of thallus laminariae, 15-20 parts of lycopodium calvatum, 10-20 parts of dandelion, 10-25 parts of spina gleditsiae,
3-6 parts of radix bupleuri.
Preferably, the Chinese medicine composition is made of the Chinese medicine material of following parts by weight: 15 parts of oldenlandia diffusa, Radix Astragali
15 parts, 15 parts of Tupistra, 15 parts of lycopodium calvatum, 15 parts of luffa, 15 parts of thallus laminariae, 15 parts of fritillaria thunbergii, 12 parts of Poria cocos, 15 parts of trigone,
15 parts of leech, 12 parts of Radix Curcumae, 15 parts of Prunella vulgaris, 15 parts of curcuma zedoary, 15 parts of Sargent gloryvine, 12 parts of dandelion, 12 parts of spina gleditsiae, 3 parts of radix bupleuri.
Preferably, the Chinese medicine material is Chinese medicinal granule.
Preferably, the Chinese medicine composition also includes the auxiliary material pharmaceutically allowed.
Preferably, the Chinese medicine composition is decoction, tablet, capsule, granule or oral solution.
The present invention also provides use of the Chinese medicine composition of above-mentioned treatment breast cancer in preparation treatment breast cancer medicines
On the way.
Chinese medicine thinks that the occurrence and development of breast cancer are the inside and outside results because interacting for a long time.Vigour virtual loss immunity of organism
Hypofunction, exopathogen are taken advantage of a weak point, with the passing of time perverse trend is accumulated into poison；QI-blood circulation is unsmooth, the phlegm blood coagulation stasis of blood, raw in cancer poison；Cancer poison one
Denier is formed, and retardance in vivo, and can induce turbid phlegm, hemostasis, wet turbid, heat toxin, gradually forms tangible lump." void ", " poison ",
" phlegm ", " stasis of blood " influence each other, interact, and promote the occurrence and development and derivation of breast cancer.Patient with breast cancer is mostly with the positive deficiency of vital energy
It is weak for this, to accumulate in cult poison, blood stasis phlegm coagulate for mark, cancer poison, obstruction by phlegm have highly important work during progression of disease
With.Therefore according to differentiation of tcm, the treatment of breast cancer focuses on qi and activate blood circulation detoxicating and resolving a mass.For breast cancer " void ",
The pathological characteristic of " poison ", " phlegm ", " stasis of blood " obtains Chinese medicine of the invention under the guidance of " suppressing and strengthening cancer detoxicating and resolving a mass " principle of reatment
Composition, it is withered by Poria cocos, Radix Astragali, lycopodium calvatum, luffa, thallus laminariae, fritillaria thunbergii, oldenlandia diffusa, trigone, leech, Radix Curcumae, summer
The composition such as grass.
In Chinese medicine composition of the invention, Radix Astragali, Tupistra, oldenlandia diffusa are monarch drug in a prescription；Poria cocos, trigone, luffa, Zhejiang
Fritillaria, leech, Radix Curcumae, Prunella vulgaris, curcuma zedoary, Sargent gloryvine are ministerial drug；Thallus laminariae, lycopodium calvatum, dandelion, spina gleditsiae are adjutant；Radix bupleuri is
Make medicine.Wherein Radix Astragali, Poria cocos QI invigorating eliminating toxic, clearing damp and promoting diuresis；Fritillaria thunbergii, thallus laminariae, oldenlandia diffusa, Prunella vulgaris are clearing heat and detoxicating, soft
Hard dissipating bind；Lycopodium calvatum, luffa dispelling wind and removing obstruction in the meridians；Trigone, leech, Radix Curcumae breaking blood and promoting the circulation of qi, disperse accumulation dissipate the stasis of blood；Qi and activate blood circulation is played altogether in full side
The effect of detoxicating and resolving a mass.
Tupistra, oldenlandia diffusa, curcuma zedoary, trigone, Radix Astragali play anticancer effect.Oldenlandia diffusa can mitigate chemotherapeutic
Cytotoxic effect of the object to breast cancer cell.In addition, Poria cocos has apoptosis-inducing activity.Radix Curcumae can inhibit breast cancer thin
The migration and invasion of born of the same parents.Prunella vulgaris can induce Apoptosis of Breast Cancer and play anti-tumor activity.Prunella vulgaris can also Prophylactic chemotherapy
Caused side effect.
Beneficial effects of the present invention:
(1) Chinese medicine composition of the invention can promote breast cancer mouse apoptosis of tumor cells, the inhibition having to breast cancer
Effect；
(2) Chinese medicine composition of the invention can inhibit tumor proliferation by the expression of up-regulation caspase-3.
Detailed description of the invention
Fig. 1 is tumor-bearing mice living imaging testing result.
After Fig. 2 a is administration 7 days, the Apoptosis displaing micro picture of the TUNEL method detection of each group mammary gland of mouse tissue
(TUNEL, × 200).
After Fig. 2 b is administration 14 days, the Apoptosis displaing micro picture of the TUNEL method detection of each group mammary gland of mouse tissue
(TUNEL, × 200).
After Fig. 3 a is administration 7 days, the cle-caspase-3 albumen of each group mammary gland of mouse tissue and caspase-3 albumen
Western Blot testing result.
After Fig. 3 b is administration 14 days, the cle-caspase-3 albumen of each group mammary gland of mouse tissue and caspase-3 albumen
Western Blot testing result.
Specific embodiment
Below in conjunction with drawings and examples, the following further describes the technical solution of the present invention.
Exist to study the Chinese medicine composition (the hereinafter referred to as suppressing and strengthening cancer balance side II) for the treatment of breast cancer of the invention
The mechanism of action played in breast cancer tumour, the application utilize the mouse mastopathy cell 4T1-Luc of luciferase label, establish
The mouse breast cancer cell model of luciferase label observes tumor-bearing mice in different time points using whole body optical imaging system
Breast cancer tumor growth situation, and detect suppressing and strengthening cancer balance the side II to apoptosis of tumor cells and apoptosis of tumor cells albumen
The influence of cle-caspase-3, caspase-3 expression.Key factor of the Caspase-3 as various apoptotic signal accesses swashs
Caspase-3 after work can directly facilitate the generation of apoptosis pathway, induce tumour cell mouse apoptosis.Cle-caspase-3 egg
The white active form for caspase-3.
1 material
1.1 experimental animals and medicinal material
SPF grades of pure lines BAlB/C-nu mouse, female, 60, weight 20g ± 2g, 6 week old, from the experiment of Beijing dimension tonneau China
Zoo technical Co., Ltd buys (credit number: SCXK2016-0006), raises in Hua Zhong Agriculture University's animal experimental center.
Suppressing and strengthening cancer balances II Fang Zucheng: 15 grams of oldenlandia diffusa, 15 grams of Radix Astragali, 15 grams of Tupistra, 15 grams of lycopodium calvatum, luffa 15
Gram, 15 grams of thallus laminariae, 15 grams of fritillaria thunbergii, 12 grams of Poria cocos, 15 grams of trigone, 15 grams of leech, 12 grams of Radix Curcumae, 15 grams of Prunella vulgaris, curcuma zedoary 15
Gram, 15 grams of Sargent gloryvine, 12 grams of dandelion, 12 grams of spina gleditsiae, 3 grams of radix bupleuri, Chinese medicine each component selects the limited public affairs of Jiangyin Tian Jiang medicine company
The Chinese medicinal granule for taking charge of production is provided by Central-South Chinese medicine pharmacy, hospital, Wuhan University.The particulate component of Chinese medicine each component is being added
Dissolution is mixed in distilled water after heat, prepares the suppressing and strengthening cancer balance side II of various concentration；Low molecular weight heparin is purchased from Wuhan
The Central-South hospital's pharmaceutical chemists of university.The growth that can inhibit breast tumor tissue known to low molecular weight heparin, as positive controls.
1.2 main agents and instrument
The mouse mammary carcinoma cell line 4T1-Luc (remote enlightening biology Co., Ltd, Shanghai section) of luciferase label；D- fluorescence
Plain sylvite (D-Luciferin Potassium Salt, Goldbio company, the U.S.)；Small animal living body imaging system (Xenogen
IVIS LuminaII) (model: Lumina II, manufacturer: Caliper)；Fetal calf serum (Gibco company)；DMEM(Hyclone
Company)；Haematoxylin, TUNEL cell apoptosis detection kit (development process), RIPA (strong) histocyte rapid cleavage liquid, BCA egg
White concentration measuring kit (enhanced) (bioswamp)；IMS ias (the limited public affairs of Wuhan Hua Lian section biotechnology
Department)；Microscope (Nikon company)；Reverse Transcriptase kit (TAKARA)；YBR Green PCR kit (KAPA
Biosystems)；Trizol(ambion)；Fluorescence quantitative PCR instrument Real-Time System, gel imaging system
Universal Hood II(BIO-RAD)；Protein G Magnetic Beads (magnetic bead) (Cell Signaling)；Egg
White matter Marker (Thermo)；PVDF transfer membrane, chemical illuminating reagent (millipore)；Caspase-3 antibody (abcam)；Entirely
Robotics luminescence analyzer (Shanghai day energy)；The excellent Pood laboratory Superpure water machine of UPT (French MilliPORE).
2 methods
2.1 cell culture:
4T1-luc mouse mastopathy cell is placed in 37 DEG C, 5%CO2In incubator, with containing 10% fetal calf serum and 1% pair
It is cultivated in 1640 cultures of anti-(100 μ g/mL penicillin and 100 μ g/mL streptomysins).
The preparation of 2.2 breast cancer mouse models and grouping
The bioluminescence marker activity of 4T1-luc mouse mastopathy cell is detected after 99% or more, logarithmic growth phase
Cell preparation 1 × 107/ mL cell suspension.
60 BAlB/C-nu female mices are divided into 6 groups, respectively control group, model group, low molecular weight heparin group, high agent
Amount group, middle dose group, low dose group.Control group is normal mouse, and model group is inoculated with breast cancer cell but does not treat, other components
Not Jie Zhong drug treatment after breast cancer cell, as treatment group.High dose group, middle dose group and low dose group give suppression cancer respectively
The various dose of the strengthening balancing side II.It randomly selects 10 and is only used as Normal group (non-modeling), every mouse of remaining mouse
The lower injection 20 μ L inoculation of cream pad, prepares breast cancer mouse model.First day after modeling inoculating cell, it is imaged using small animal living body
System detection effect of inoculation, with total number of photons (p/s/mm of the tumour cell detected2) indicate to be inoculated with into the swollen of cream pad position
Oncocyte quantity, selection are inoculated with uniform mouse and are included in experiment, after 50 mouse whole modelings successfully, are randomly divided into 5 groups: mould
Type group, low molecular weight heparin group, the high, medium and low dosage group of the suppressing and strengthening cancer balance side II, every group each 10.It is secondary after modeling success
Day, high, medium and low dosage group gives 1.5g/mL, 3g/mL, 6g/mL suppressing and strengthening cancer balance II square Chinese medicine stomach-filling respectively, and daily one
It is secondary；Low molecular weight heparin group gives low molecular weight heparin intraperitoneal injection (1500U/Kg), once a day；Model group and control group are given
Dosage physiological saline stomach-filling, once a day.The daily stomach-filling amount of every mouse is 0.2ml.The observation of 2.3 bioluminescence imaging technologies
It is lived after inoculation using toy within the 14th day after next day, modeling success the 7th day after next day, administration, after administration respectively
Body imaging system observes transplantable tumor number, size and distribution.Tumor size is with total number of photons (p/s/ of the tumour cell detected
mm2) indicate.Detect preceding 3% isoflurane deep anaesthesia mouse 5min, 150mg/kg Luciferin (fluorescein the sylvite) (bottom 3mg
Object/only) intraperitoneal injection, it images after 10min, total shine for detecting tumour cell counts, and with calliper to measure tumour major diameter and minor axis,
Calculate gross tumor volume, V=(major diameter × minor axis2)/2。
2.4 tumor tissue specimen collecting
Respectively upon administration 7d, 14d when each group take 5 mouse at random, win transplanting tumor tissue.
2.5 TUNEL methods detect apoptosis of tumor cells
Proteinase K working solution, PBS is added dropwise in the dewaxing after dehydration, transparent, waxdip, slice, roasting piece of mammary gland transplantation tumor tissue
Washing 3 times.TUNEL reaction mixture is added dropwise on sample, being protected from light incubation 60min, after washing plus Converter-POD (is converted
Agent-POD) it is incubated for 30min in being protected from light on sample, DAB developing solution is added dropwise after washing, color development stopping after color development at room temperature 10min, then
Successively transparent by Harris haematoxylin redyeing and dehydration, the slice dried is in light microscopic observation and acquires image.TUNEL is in situ
Apoptosis result judgement: karyopyknosis, chromatic agglutination are blocking or side integrates, is in brown, yellow or brown color tinter as apoptosis
Cell.Every group of per time point (7d, 14d after administration) takes 3 mouse to be detected respectively, counts 3 visual field mammary gland transplantations
Apoptotic cell number in tumor, and calculate apoptotic index.Apoptotic index=TUNEL staining positive cells number/total number of cells ×
100%.
2.6 PCR measure the expression of the mRNA of caspase-3
It takes 0.1g to be organized in the homogenate tube of the Trizol of 1mL and extracts total serum IgE by kit specification.It is tried using reverse transcription
RNA reverse transcription is cDNA according to 20 μ L reaction systems by agent box, reaction condition: 42 DEG C, 60min；70 DEG C, 15min；16 DEG C,
hold.The cDNA of synthesis is saved backup in -20 DEG C of standing 15min.Amplimer is by Nanjing Genscript Biotechnology Co., Ltd.
Synthesis, primer sequence are shown in Table 1.Using GADPH as reference gene, carries out real time PCR amplification and detect sample Caspase-3 mRNA table
It reaches, reaction condition: 95 DEG C, 3min；95 DEG C, 5sec；56 DEG C, 10sec；72 DEG C, 25sec；39 circulations (cycles)；65 DEG C,
5Sec；95 DEG C, 50Sec.Each sample is all provided with 3 multiple holes.Data carry software analysis (qBase PLUS) using instrument, with 2
-ΔΔCtCalculate the relative expression quantity of purpose mRNA.
1 PCR primer sequence of table
The expression of 2.7 Western Blot measurement cle-caspase-3, caspase-3
Every group of per time point (7d, 14d after administration) materials, randomly select the breast tissue of three mouse, tissue fills
After dividing grinding, cracking, centrifugation, supernatant is taken, BCA method is used to measure sample protein concentration.Each sample takes 10 μ g loadings, prepares
12% separation gel and 5% concentration glue, carry out constant pressure electrophoresis, 300mA constant current transferring film rear enclosed by concentration glue 80V, separation gel 120V
Liquid chamber temperature closes 1h.4 DEG C of primary antibody (the caspase-3 dilution ratio of Lepus is 1:500, and the cle-caspase-3 of Lepus is dilute overnight
Releasing ratio is 1:1000), secondary antibody (skim milk of HRP-Goat anti Rabbit and 5% is diluted at 1:10000), room temperature
It is incubated for 1h, then washes film 3 times with PBST, each 5min.Film is placed in darkroom, illustrates to develop by ECL kit, after will
Film is placed in Full-automatic chemiluminescence analyzer and detects, and reads related band gray value by TANON GIS software.
3 statistical methods
It is analyzed using 21.0 statistical software of SPSS, metric results are indicated with (x- ± s).Using single factor test variance point
Analysis is that difference is statistically significant with P < 0.05.
4 interpretations of result
4.1 observe the number of photons of transplantable tumor tumour cell under living imaging
As shown in Figure 1, being 4TI-Luc breast cancer mouse living imaging result.Total number of photons of transplantable tumor tumour cell is such as
Shown in table 2.4T1-luc cell inoculation is imaged immediately after BAlB/C-nu mouse, inoculating cell, and the vaccination of whole mouse is equal
Have luminous.And 7d, 14d observe transplantable tumor growth of tumour cell situation after 1d, administration after modeling success.Please refer to table
2, increase of the model group with observation number of days, total number of photons increase, the enhancing of tumour luminous intensity.And each treatment group is in modeling success
The total number of photons of 1d afterwards is most strong, and 7d and the total number of photons of 14d gradually decrease, and has notable difference with model group.It is more same
Time point each treatment group, in 7d, total number of photons suppressing and strengthening cancer is balanced in the high dose group ratio of the side II, low dose group obviously drops
It is low, and high dose group and low molecular weight heparin group no significant difference.And in 14d, with suppressing and strengthening cancer balance II prescription amount
Increase, total number of photons is substantially reduced, and high dose group ﹤ middle dose group ﹤ low dose group.And number of photons suppressing and strengthening cancer balances No. II
Square high dose group ﹤ low molecular weight heparin group.
Total number of photons (p/s/mm of 2 transplantable tumor tumour cell of table2)
4.2 transplantable tumor tumour inhibiting rates
Each group transplantable tumor volume is as shown in table 3.First day after modeling success, each group transplantable tumor volume no significant difference.
The 7th day after administration, model group volume is significantly increased.The high agent of low molecular weight heparin group, the suppressing and strengthening cancer balance side II
Compared with model group, volume be may be significantly smaller for amount group, the middle dose group of the suppressing and strengthening cancer balance side II.And the suppressing and strengthening cancer balance side II
Low dose group no significant difference compared with model group.Compare no significant difference between each treatment group.
The 14th day after administration, low molecular weight heparin group, the high dose group of the suppressing and strengthening cancer balance side II, suppressing and strengthening cancer balance II
Compared with model group, volume be may be significantly smaller for the middle dose group of number side, the low dose group of the suppressing and strengthening cancer balance side II.More various treatments
Between group, low molecular weight heparin group and suppressing and strengthening cancer balance No. II square high dose group, suppressing and strengthening cancer balance No. II square middle dose group without
Notable difference.
3 each group transplantable tumor volume of table
The apoptosis situation of 4.3 TUNEL methods detection mammary gland of mouse tissue tumor cells
The apoptosis situation of breast tissue sample tumour cell is detected by TUNEL.As shown in Fig. 2 a, Fig. 2 b, control group
It there's almost no apoptotic cell with model group.In Fig. 2 a and Fig. 2 b, lower right corner black region is 50 μm of scale bar.
And each time point (7d, 14d after administration), suppressing and strengthening cancer balance No. II (high, medium and low dosage) group and low molecule liver
Element group apoptotic index is significantly raised.And suppressing and strengthening cancer balance II high dose group > suppressing and strengthening cancer balance II middle dosage > presses down cancer
Strengthening balancing II low dose group.Compare low molecular weight heparin group and suppressing and strengthening cancer balance II high dose group, 7d apoptotic index
No significant difference between two groups, 14d apoptotic index suppressing and strengthening cancer balance II high dose group > low molecular weight heparin group.
And observation different time points apoptosis of tumor cells situation, each treatment group's apoptotic index 14d > 7d.Such as table 4.
4 each group mammary gland of mouse cell TUNEL stained positive rate of table compares
4.4 mammary gland of mouse tissue caspase-3 mRNA expressions of results
The results are shown in Table 5 for each group breast tissue caspase-3 mRNA expression, and the expression quantity of control group is considered as 1.
The 7th day after administration, compared to the control group, model group caspase-3 mRNA expression is substantially reduced；Compared to model group, suppressing and strengthening cancer is flat
The expression apparent increase of No. II (high, medium and low dosage) group, low molecular weight heparin group caspase-3 mRNA of weighing, and suppressing and strengthening cancer is flat
Apparent dosage correlation is presented in the expression of No. II high, medium and low three group caspase-3 mRNA of weighing apparatus, and mRNA expresses > in high >
It is low.And low molecular weight heparin group and suppressing and strengthening cancer balance II high dose group no significant difference.
14th day, compared to the control group, model group caspase-3 mRNA expression was substantially reduced；Compared to model group, presses down cancer and help
Positive balance II (high, middle dosage) group, the expression of low molecular weight heparin group caspase-3 mRNA are significantly raised, and mRNA expression suppression
Strengthening cancer balances II high dose group > low molecular weight heparin group > suppressing and strengthening cancer balance II middle dose group > suppressing and strengthening cancer balance
II low dose group.
And compare this 2 time points of 7d, 14d, the expression of each treatment group caspase-3 mRNA is presented significant timeliness and closes
System, 14d > 7d.
5 each group breast tissue caspase-3 mRNA expression of table
4.5 mammary gland of mouse tissue cle-caspase3, caspase-3 protein expression results
Western Blot result is as shown in Figure 3a and Figure 3b shows.The gray value of electrophoretic band is as shown in table 6.The 7th after administration
It, compares Normal group, and model group caspase-3 protein expression is substantially reduced；Compared to model group, suppressing and strengthening cancer balances No. II
(high, medium and low dosage) group, the expression of low molecular weight heparin group caspase-3 albumen are significantly raised, and suppressing and strengthening cancer balances No. II
Apparent dosage correlation is presented in the expression of high, medium and low three groups caspase-3 albumen, expressing quantity: suppressing and strengthening cancer balance
II high dose group > suppressing and strengthening cancer balances II middle dose group > suppressing and strengthening cancer and balances II low dose group.And low molecular weight heparin
Group balances II high dose group no significant difference with suppressing and strengthening cancer.
14th day, Normal group is compared, model group caspase-3 protein expression is substantially reduced；Compared to model group, press down cancer
Strengthening balancing II (high, medium and low dosage) group, the expression of low molecular weight heparin group caspase-3 albumen are significantly raised, and press down cancer and help
Positive balance II high dose group > protein expression low molecular weight heparin group > suppressing and strengthening cancer balances II middle dose group > suppressing and strengthening cancer
Balance II low dose group.
And comparing this 2 time points of 7d, 14d, significant timeliness is presented in the expression of each treatment group caspase-3 albumen
Relationship, 14d > 7d.
Compare the cle-caspase-3 protein expression in breast tissue, cle-caspase-3 albumen and caspase-3's
Protein expression trend having the same.
6 each group breast tissue cle-caspase-3, caspase-3 protein band gray value of table compares
The application has studied the influence of " suppressing and strengthening cancer balances the side II " to mouse breast cancer 4T1-luc2 growth apoptosis.It adopts
Mouse growth situation is observed with newest bioluminescence imaging technology (biodiversity resources).Intuitive, real-time, the sensitive height of the technology,
Both individual difference can be eliminated, reduces the quantity of animal, meets animal in the repeated multiple times acquisition volume of data of same individual
" 3R " principle of experiment, and can be with observation experiment as a result, and obtaining intuitive image.
Observed by bioluminescence imaging technology when being inoculated with, after modeling success, the 7th day, total light in the 14th day Mice Body after administration
Subnumber and distribution, more each treatment group find its inhibiting effect size are as follows: suppressing and strengthening cancer to breast cancer mouse tumor inhibition effect
Balance the high dose group > middle dose group > low dose group of the side II.It is swollen that breast tissue sample is further detected by TUNEL method
The apoptosis situation of oncocyte, also obtains identical result.Illustrate that suppressing and strengthening cancer balances No. II and can promote breast cancer mouse tumour
Apoptosis.Expression quantity of this research by detection caspase-3 and cle-caspase-3 albumen, discovery suppressing and strengthening cancer balance
The high, medium and low dosage group caspase-3 in the side II and cle-caspase-3 protein expression are above model group, and the 14th after administration
Its suppressing and strengthening cancer balances No. II square high dose group and is apparently higher than low molecular weight heparin group.Illustrate that suppressing and strengthening cancer balances No. II and can pass through
Caspase-3 inducing mammary carcinogenesis apoptosis is activated, the proliferation of tumour is inhibited.
In conclusion the Chinese medicine composition (suppressing and strengthening cancer balances the side II) for the treatment of breast cancer of the invention plays breast cancer
To certain inhibiting effect, activation caspase-3 expression, inducing mammary carcinogenesis apoptosis can be passed through.
It is discussed in detail although the contents of the present invention have passed through above preferred embodiment, but it should be appreciated that above-mentioned
Description is not considered as limitation of the present invention.After those skilled in the art have read above content, for of the invention
A variety of modifications and substitutions all will be apparent.Therefore, protection scope of the present invention should be limited to the appended claims.
Claims (6)
1. a kind of Chinese medicine composition for treating breast cancer, which is characterized in that be made of the Chinese medicine material of following parts by weight: Radix Astragali
15-25 parts, 15-25 parts of Tupistra, 15-25 parts of oldenlandia diffusa, 10-20 parts of Poria cocos, 15-20 parts of trigone, luffa 15-20
Part, 15-20 parts of fritillaria thunbergii, 15-20 parts of leech, 10-20 parts of Radix Curcumae, 15-20 parts of Prunella vulgaris, 15-20 parts of curcuma zedoary, Sargent gloryvine 15-20
Part, 10-20 parts of thallus laminariae, 15-20 parts of lycopodium calvatum, 10-20 parts of dandelion, 10-25 parts of spina gleditsiae, 3-6 parts of radix bupleuri.
2. the Chinese medicine composition for the treatment of breast cancer described in claim 1, which is characterized in that the Chinese medicine composition is by following
The Chinese medicine material of parts by weight is made: 15 parts of oldenlandia diffusa, 15 parts of Radix Astragali, 15 parts of Tupistra, 15 parts of lycopodium calvatum, luffa 15
Part, 15 parts of thallus laminariae, 15 parts of fritillaria thunbergii, 12 parts of Poria cocos, 15 parts of trigone, 15 parts of leech, 12 parts of Radix Curcumae, 15 parts of Prunella vulgaris, curcuma zedoary 15
Part, 15 parts of Sargent gloryvine, 12 parts of dandelion, 12 parts of spina gleditsiae, 3 parts of radix bupleuri.
3. the Chinese medicine composition for the treatment of breast cancer according to claim 1, which is characterized in that during the Chinese medicine material is
Medicine composition particle.
4. the Chinese medicine composition for the treatment of breast cancer according to claim 1, which is characterized in that the Chinese medicine composition is also
Include the auxiliary material pharmaceutically allowed.
5. the Chinese medicine composition for the treatment of breast cancer according to claim 1, which is characterized in that the Chinese medicine composition is
Decoction, tablet, capsule, granule or oral solution.
6. purposes of the Chinese medicine composition for the treatment of breast cancer according to claim 1 in preparation treatment breast cancer medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910232807.0A CN109847039B (en) | 2019-03-26 | 2019-03-26 | Traditional Chinese medicine composition for treating breast cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910232807.0A CN109847039B (en) | 2019-03-26 | 2019-03-26 | Traditional Chinese medicine composition for treating breast cancer and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109847039A true CN109847039A (en) | 2019-06-07 |
| CN109847039B CN109847039B (en) | 2022-01-04 |
Family
ID=66901972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910232807.0A Active CN109847039B (en) | 2019-03-26 | 2019-03-26 | Traditional Chinese medicine composition for treating breast cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109847039B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879857A (en) * | 2006-05-08 | 2006-12-20 | 周晶 | Medicinal powder for treating mammary gland disease |
| CN101810827A (en) * | 2010-04-14 | 2010-08-25 | 郑文修 | Chinese medicinal preparation for treating mammary aggregation |
| CN106266931A (en) * | 2015-06-01 | 2017-01-04 | 刘健享 | A kind of Chinese medicine composition treating gynecological tumor and preparation method thereof |
| CN106581572A (en) * | 2015-10-16 | 2017-04-26 | 四川洪乾耀中医药研发有限公司 | Oral medicine for treating breast cancer |
-
2019
- 2019-03-26 CN CN201910232807.0A patent/CN109847039B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879857A (en) * | 2006-05-08 | 2006-12-20 | 周晶 | Medicinal powder for treating mammary gland disease |
| CN101810827A (en) * | 2010-04-14 | 2010-08-25 | 郑文修 | Chinese medicinal preparation for treating mammary aggregation |
| CN106266931A (en) * | 2015-06-01 | 2017-01-04 | 刘健享 | A kind of Chinese medicine composition treating gynecological tumor and preparation method thereof |
| CN106581572A (en) * | 2015-10-16 | 2017-04-26 | 四川洪乾耀中医药研发有限公司 | Oral medicine for treating breast cancer |
Non-Patent Citations (2)
| Title |
|---|
| 叶太生等: "开口箭皂苷对S-180肉瘤细胞荷瘤小鼠NF-κB mRNA的影响及其机制研究 ", 《湖北中医药大学学报》 * |
| 彭艳芳等: "张莹雯教授诊治肿瘤的学术思想初探", 《世界中医药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109847039B (en) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Resveratrol alleviates temporomandibular joint inflammatory pain by recovering disturbed gut microbiota | |
| CN103222988B (en) | A kind of American-cockroach-extract and its preparation method and application | |
| Zhen et al. | Pteryxin attenuates LPS-induced inflammatory responses and inhibits NLRP3 inflammasome activation in RAW264. 7 cells | |
| Chen et al. | Different processed products of Curcumae Radix regulate pain-related substances in a rat model of Qi Stagnation and blood stasis | |
| CN104808004B (en) | METRNL albumen is as the application of diagnosis of colon cancer mark and test kit | |
| CN102805756B (en) | Application of extract of Chimonanthus Salicifolius. S.Y.H. in preparation of gastric cancer treating medicine | |
| CN104188949B (en) | Purposes of the chlorogenic acid in the medicine for preparing treatment mesoglioma | |
| CN105395771B (en) | A kind of new warm kidney production of sperm drink and preparation method thereof | |
| CN108452009A (en) | A kind of application including Common Leafflower Herb, rainbow conk, Radix Salviae Miltiorrhizae and the Chinese medicine composition of Asian puccoon in the drug for preparing treatment liver cancer | |
| CN109847039A (en) | A kind of Chinese medicine composition and application thereof for treating breast cancer | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| WO2021169682A1 (en) | Traditional chinese medicine composition, and preparation method therefor and application thereof | |
| CN101947288A (en) | Medicine for treating enteritis-related diseases | |
| CN101380359A (en) | Jiangu capsules and preparation method thereof | |
| CN108452008A (en) | A kind of application including Common Leafflower Herb, rainbow conk, Radix Salviae Miltiorrhizae and the Chinese medicine composition of Asian puccoon in preparing the drug for inhibiting recurrence of PHC | |
| CN105055872B (en) | Chinese medicine composition and its preparation method and application for treating Alzheimer disease | |
| CN100388925C (en) | Medication composition of replenishing qi to invigorate the spleen, preparation method and usage | |
| CN110389179A (en) | A kind of detection method of Chinese medicine composition | |
| CN103961638A (en) | Traditional Chinese medicine composition with anticancer effect and new purpose thereof | |
| CN100450545C (en) | Application of musculus growth inhibin for preparing anticarcinogen | |
| CN105030948B (en) | A kind of new application of pharmaceutical composition and its preparation | |
| US10004713B2 (en) | Uses of chlorogenic acid in the preparation of medicaments for treatment of oligodendroglioma | |
| CN106334055A (en) | Chinese medicinal composition for treatment of cerebral ischemia reperfusion injury and application thereof | |
| CN104055898B (en) | The Chinese medicine composition of poison is let out in a kind of spleen invigorating for the treatment of myelocytic leukemia | |
| Lei et al. | Dahuang—Taoren, a botanical drug combination, ameliorates adenomyosis via inhibiting Rho GTPases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |